IBRX — Immunitybio Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapMomentum Trap

Annual cashflow statement for Immunitybio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-350	-417	-584	-414	-351
Depreciation
Deferred Taxes
Non-Cash Items	80.3	69.6	195	24.3	85.3
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-19.1	-8	3.98	-19.4	-54.3
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Cash from Operating Activities	-274	-338	-367	-391	-305
Capital Expenditures	-33.6	-99.4	-30.6	-6.89	-4.25
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Software Development Costs
Other Investing Cash Flow Items	-51.3	127	0.114	-5.36	-146
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-84.9	27.3	-30.5	-12.2	-150
Financing Cash Flow Items	1.02	-0.339	0	0	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	505	234	558	282	400
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	146	-76.3	161	-122	-54.5